Catalog No.
PHE83701
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human BRCA2 (Lys2308-His2537).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:200, WB: 1:500-1:4000
Target
BRCA2, FANCD1, FACD, Fanconi anemia group D1 protein, Breast cancer type 2 susceptibility protein
Concentration
0.64 mg/ml
Purification
Purified by antigen affinity column.
Accession
P51587
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Genomic profiles of pathogenic and moderate-penetrance germline variants associated with risk of early-onset lung adenocarcinoma., PMID:40516820
New Treatment Approaches for Triple-Negative Breast Cancer., PMID:40460322
Unraveling SET: Exploring ovarian high-grade serous carcinoma and its BRCA1/2 immunoexpression., PMID:40405589
Advances in Targeted Therapy for Metastatic Prostate Cancer., PMID:40299225
The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models., PMID:40297621
Combined Chemotherapy-Immunotherapy for Advanced Biliary Tract Cancer (BTC): A Clinical, Genomic, and Biomarker Analysis., PMID:40167580
Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance., PMID:40141188
Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer., PMID:40034244
Tislelizumab plus AG regimen for long-term CR in 2 patients with metastatic BRCA-mutation pancreatic cancer: A case report., PMID:39969335
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence., PMID:39914385
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms., PMID:39572842
Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta-Analysis., PMID:39466473
[The evolution of a luminal breast cancer to a triple-negative and its impact on disease control with sacituzumab govitecan.]., PMID:39446008
Neutralization of the autophagy-repressive tissue hormone DBI/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) enhances anticancer immunosurveillance., PMID:39419485
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial., PMID:39293514
PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments., PMID:39246166
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study., PMID:39116683
Analysis of translesion polymerases in colorectal cancer cells following cetuximab treatment: A network perspective., PMID:39102671
Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer., PMID:39092645
Using Trastuzumab Deruxtecan to treat advanced metastatic breast cancer in patients with varying HER2 expression levels: A single-center experience in Taiwan., PMID:38996157
Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer., PMID:38920970
Complete remission following pembrolizumab in a man with mCRPC with both microsatellite instability and BRCA2 mutation., PMID:38920278
Epstein-Barr virus deubiquitinating enzyme BPLF1 is involved in EBV carcinogenesis by affecting cellular genomic stability., PMID:38875930
Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors., PMID:38786089
Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?, PMID:38663167
Characterization of immortalized ovarian epithelial cells with BRCA1/2 mutation., PMID:38615309
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations., PMID:38592722
Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy., PMID:38551024
PARP Inhibitors for Breast Cancer Treatment: A Review., PMID:38512229
Clinical sequencing defines the somatic and germline mutation landscapes of Chinese HER2-Low Breast Cancer., PMID:38403109
HER2-Low Expression in Male Breast Cancer: Results from a Multicenter Series in Italy., PMID:38339299
MicroRNA signatures differentiate types, grades, and stages of breast invasive ductal carcinoma (IDC): miRNA-target interacting signaling pathways., PMID:38326829
Remarkable response to pazopanib plus vivolumab in a patient with pericardial synovial sarcoma carrying a novel genotype BRCA2 c.968dupT: A case report., PMID:38323364
Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer., PMID:38309723
Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer., PMID:38288862
Systemic Treatment of Patients With Metastatic Breast Cancer: ASCO Resource-Stratified Guideline., PMID:38206277
Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer., PMID:38170790
BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients., PMID:38167124
Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS)., PMID:38137385
Targeted inhibition of the ATR/CHK1 pathway overcomes resistance to olaparib and dysregulates DNA damage response protein expression in BRCA2MUT ovarian cancer cells., PMID:38114660
Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial., PMID:38109438
PARP Inhibitor Sensitizes BRCA-mutant Pancreatic Cancer to Oxaliplatin by Suppressing the CDK1/BRCA1 Axis., PMID:38030179
BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy., PMID:38017453
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study., PMID:37939124
Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins., PMID:37909041
Survey of NF1 inactivation by surrogate immunohistochemistry in ovarian carcinomas., PMID:37820398
Three cases of colon cancer in four generations of the Saudi family, caused by endogamous germline mutations., PMID:37715401
Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides "one-two punch" opportunity with anti-PD-L1 therapy in colorectal cancer., PMID:37702298
LepR+ niche cell-derived AREG compromises hematopoietic stem cell maintenance under conditions of DNA repair deficiency and aging., PMID:37584437
Identification of RAD51 foci in cancer-associated circulating cells of patients with high-grade serous ovarian cancer: association with treatment outcomes., PMID:37541687
For research use only. Not for human or drug use.
